BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (TSX VENTURE: IXS) (OTCBB: IXSBF), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, today announced that Dr. Carlos L. Arteaga, Vice Chancellor’s Chair in Breast Cancer Research and Professor of Medicine and Cancer Biology, Vanderbilt-Ingram Comprehensive Cancer Center, has joined InNexus’ newly formed Scientific Advisory Board. He joins Dr. J. Donald Capra, President Emeritus of the Oklahoma Medical Research Foundation and InNexus SAB Chairman, Dr. Thomas Kindt and Dr. John D. Minna.
